REPLIGEN CORP Total Contract Liability
REPLIGEN CORP (RGEN) had Total Contract Liability of $8.50 million as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2025-08-07
- 2025-06-30: Contract with Customer, Liability $8.50M.
- 2025-03-31: Contract with Customer, Liability $5.34M.
- 2024-12-31: Contract with Customer, Liability $16.37M.
- 2024-09-30: Contract with Customer, Liability $15.37M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2025-06-30 | $8.50M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $5.34M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $16.37M 10-Q · filed 2025-08-07 | |
| 2024-09-30 | $15.37M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $13.42M 10-Q/A · filed 2024-11-18 | $6.82M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $6.35M 10-Q/A · filed 2024-11-18 | $4.52M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $18.75M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $17.00M 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | $13.81M 10-Q/A · filed 2024-11-18 | |
| 2023-03-31 | $8.60M 10-Q/A · filed 2024-11-18 | |
| 2022-12-31 | $13.39M 10-Q/A · filed 2024-11-18 | |
| 2022-09-30 | $12.99M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $11.21M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $9.06M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $13.71M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $13.07M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $12.09M 10-Q · filed 2021-07-27 | |
| 2021-03-31 | $8.53M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $3.36M 10-K · filed 2022-02-17 | |
| 2020-09-30 | $3.13M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $2.75M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $1.91M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $833.00K 10-K · filed 2021-02-24 | |
| 2019-09-30 | $2.77M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $1.67M 10-Q · filed 2019-08-01 | |
| 2018-12-31 | $878.00K 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $422.00K 10-K · filed 2019-03-01 | $441.00K 10-Q · filed 2018-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |